8 meta-analysis results to guide diabetes drug choice

Study clarifies the effects of SGLT2 inhibitors and GLP1 agonists on cardiovascular and renal outcomes
doctor looking up label on pill bottle on his computer

A meta-analysis has compared SGLT2 inhibitors and GLP1 receptor agonists for their effects on cardiovascular and renal outcomes in people with type 2 diabetes.

Each drug class has been shown to improve cardiovascular and renal outcomes.